Developping gene therapies and innovative treatments for demyelinating peripheral neuropathies

OUR mission

Nervosave Therapeutics discovers and develops therapies that slow or stop a broad range of demyelinating peripheral nerve diseases. 

Our first aim is to develop best in class Gene Therapy for CMT1A patients.

We develop robust discovery programs targeting demyelinating CMT diseases and, quickly followed by young adults and other types.